专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007010499A2 DERIVATIVES OF MONOSACCHARIDES AS 5-LIPOXYGENASE INHIBITORS 审中-公开
标题翻译：单赖类药物作为5-LIPOXYGENASE抑制剂的衍生物
公开(公告)号：WO2007010499A2
公开(公告)日：2007-01-25
申请号：PCT/IB2006052497
申请日：2006-07-20
申请人： RANBAXY LAB LTD , RAY ABHIJIT , SHIRUMALLA RAJ KUMAR , MOOKHTIAR KASIM , SATTIGERI VISWAJANANI J , PALLE VENKATA P , SALMAN MOHAMMAD
发明人： RAY ABHIJIT , SHIRUMALLA RAJ KUMAR , MOOKHTIAR KASIM , SATTIGERI VISWAJANANI J , PALLE VENKATA P , SALMAN MOHAMMAD
IPC分类号： A61K31/70 , A61P11/00 , A61P11/06
CPC分类号： A61K31/70
摘要： The present invention relates to the use of derivatives of monosaccharides as 5-lipoxygenase inhibitor.
摘要翻译：本发明涉及单糖衍生物作为5-脂氧合酶抑制剂的用途。

2. 发明申请

WO2006051399A1 PIPERAZINE DERIVATIVES USEFUL AS ADRENERGIC RECEPTOR ANTAGONISTS 审中-公开
标题翻译：哌嗪衍生物作为ADRENERGIC RECEPTOR ANTAGONISTS有用
公开(公告)号：WO2006051399A1
公开(公告)日：2006-05-18
申请号：PCT/IB2005/003373
申请日：2005-11-10
申请人： RANBAXY LABORATORIES LIMITED , SALMAN, Mohammad , ANAND, Nitya , SHARMA, Somesh , KAPKOTI, Gobind, Singh , CHUGH, Anita , NANDA, Kamna
发明人： SALMAN, Mohammad , ANAND, Nitya , SHARMA, Somesh , KAPKOTI, Gobind, Singh , CHUGH, Anita , NANDA, Kamna
IPC分类号： C07D211/88 , C07D207/40 , C07D209/48 , C07D401/04 , C07D401/06 , A61K31/496 , A61P13/00
CPC分类号： C07D207/404 , C07D209/48 , C07D211/88 , C07D401/04 , C07D401/06
摘要： The present invention relates to α 1a and/or α 1d adrenergic receptor antagonists, of formula I, which can be used to treat a disease or disorder mediated through α 1a and/or α 1d adrenergic receptors. Compounds and pharmaceutical compositions described herein can be used to treat benign prostatic hyperplasia (BPH) and related symptoms thereof. Further, such compounds can be used to treat lower urinary tract symptoms that may or may not be associated with BPH. The present invention also relates to processes to prepare the described compounds, pharmaceutical compositions thereof, and methods of treating BPH or related symptoms thereof.
摘要翻译：本发明涉及式I的1α1A和/或1 / 1d肾上腺素能受体拮抗剂，其可用于治疗通过“ 1a和/或1d肾上腺素能受体。本文所述的化合物和药物组合物可用于治疗良性前列腺增生（BPH）及其相关症状。此外，这些化合物可用于治疗可能与也可能不伴有BPH的下尿路症状。本发明还涉及制备所述化合物的方法，其药物组合物，以及治疗BPH或其相关症状的方法。

3. 发明申请

WO2006032994A3 MUSCARINIC RECEPTOR ANTAGONISTS 审中-公开
标题翻译：肌肉受体拮抗剂
公开(公告)号：WO2006032994A3
公开(公告)日：2006-05-04
申请号：PCT/IB2005002823
申请日：2005-09-23
申请人： RANBAXY LAB LTD , SALMAN MOHAMMAD , SARMA PAKALA KUMARA SAVITHRU , DHARMARAJAN SANKARANARAYANAN , CHUGH ANITA , GUPTA SUMAN
发明人： SALMAN MOHAMMAD , SARMA PAKALA KUMARA SAVITHRU , DHARMARAJAN SANKARANARAYANAN , CHUGH ANITA , GUPTA SUMAN
IPC分类号： C07D471/08 , C07C215/10 , C07D207/14 , C07D211/14 , C07D211/42 , C07D211/44 , C07D211/58 , C07D223/04 , C07D243/08 , C07D295/08 , C07D295/10 , C07D307/81 , C07D317/58 , C07D401/04 , C07D487/08
CPC分类号： C07D295/088 , C07D207/14 , C07D211/14 , C07D211/42 , C07D211/44 , C07D211/58 , C07D223/04 , C07D243/08 , C07D295/108 , C07D307/81 , C07D317/58 , C07D401/04 , C07D471/08 , C07D487/08
摘要： This present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the prepration of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.
摘要翻译：本发明一般涉及毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，泌尿和胃肠系统的各种疾病，以及其它用途。本发明还涉及所述化合物的制备方法，包含所公开的化合物的药物组合物，以及通过毒蕈碱受体介导的疾病的治疗方法。

4. 发明申请

WO2006035303A1 MUSCARINIC RECEPTOR ANTAGONISTS 审中-公开
标题翻译：肌肉受体拮抗剂
公开(公告)号：WO2006035303A1
公开(公告)日：2006-04-06
申请号：PCT/IB2005/002901
申请日：2005-09-28
申请人： RANBAXY LABORATORIES LIMITED , SALMAN, Mohammad , SARMA, Pakala, Kumara, Savithru , PAL, Arani , CHUGH, Anita , GUPTA, Suman
发明人： SALMAN, Mohammad , SARMA, Pakala, Kumara, Savithru , PAL, Arani , CHUGH, Anita , GUPTA, Suman
IPC分类号： C07D221/24 , C07D405/06 , C07D409/12 , C07D401/12 , C07D405/12 , A61K31/439 , A61P11/00 , A61P13/00 , A61P1/00
CPC分类号： C07D401/12 , C07D221/24 , C07D405/06 , C07D405/12 , C07D409/12
摘要： This present invention generally relates to muscarinic receptor antagonists of Formula (I), which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the prepration of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.
摘要翻译：本发明一般涉及式（I）的毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，泌尿和胃肠系统的各种疾病。本发明还涉及所述化合物的制备方法，包含所公开的化合物的药物组合物，以及通过毒蕈碱受体介导的疾病的治疗方法。

5. 发明申请

WO2005092907A2 MONOSACCHARIDE DERIVATIVES 审中-公开
标题翻译：单糖衍生物
公开(公告)号：WO2005092907A2
公开(公告)日：2005-10-06
申请号：PCT/IB2005000803
申请日：2005-03-29
申请人： RANBAXY LAB LTD , SATTIGERI VISWAJANANI JITENDRA , ARORA SUDERSHAN K , SALMAN MOHAMMAD , PALLE VENKATA P , YADAV GYAN CHAND , TANWAR MADAN PAL , MUKHERJEE ASHIS , NARAYANAN RAMAMURTHY , RAUF ABDUL REHAMAN ABDUL , NAIK KESHAV PRABHAKAR , SONI AJAY , RAY ABHIJIT , SHIRUMALLA RAJ KUMAR , MOOKHTIAR KASIM ABBAS
发明人： SATTIGERI VISWAJANANI JITENDRA , ARORA SUDERSHAN K , SALMAN MOHAMMAD , PALLE VENKATA P , YADAV GYAN CHAND , TANWAR MADAN PAL , MUKHERJEE ASHIS , NARAYANAN RAMAMURTHY , RAUF ABDUL REHAMAN ABDUL , NAIK KESHAV PRABHAKAR , SONI AJAY , RAY ABHIJIT , SHIRUMALLA RAJ KUMAR , MOOKHTIAR KASIM ABBAS
IPC分类号： A61K31/70 , A61K31/7028 , A61K31/7042 , C07H3/02 , C07H9/04 , C07H15/00 , C07H
CPC分类号： C07H9/04 , C07H3/02 , C07H15/00
摘要： The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, and other inflammatory and/or autoimmune disorders, using the compounds are also provided.
摘要翻译：本发明涉及作为抗炎剂的单糖衍生物。本文中的化合物障碍可用于抑制和预防炎症和相关病症，包括炎症和自身免疫性疾病，例如支气管哮喘，类风湿性关节炎，I型糖尿病，多发性硬化，同种异体移植排斥或银屑病。还提供了含有本文公开的化合物的药理学组合物和使用该化合物治疗支气管哮喘，慢性阻塞性肺病，类风湿性关节炎，多发性硬化，I型糖尿病，牛皮癣，同种异体移植物排斥和其它炎性和/或自身免疫性疾病的方法。

6. 发明申请

WO2005058813A2 ANTIDIABETIC AGENTS 审中-公开
标题翻译：抗菌剂
公开(公告)号：WO2005058813A2
公开(公告)日：2005-06-30
申请号：PCT/IB2004/004143
申请日：2004-12-15
申请人： RANBAXY LABORATORIES LIMITED , SATTIGERI, Jitendra A. , SALMAN, Mohammad
发明人： SATTIGERI, Jitendra A. , SALMAN, Mohammad
IPC分类号： C07D
CPC分类号： C07D417/10
摘要： Provided herein are alkynyl derivatives, which have PPAR agonist activity, and can be used as antidiabetic compounds. Compounds disclosed herein can be used for the treatment of diabetes and diabetes-associated complications, to diseases and conditions in which insulin resistance is a pathophysiological mechanism, and to diseases or conditions such as Type II diabetes, dyslipidaemia, hypertension, coronary heart disease, cardiovascular disease, atherosclerosis, nephrosclerosis, polycystic ovarian syndrome, eating disorders, diabetes nephropathy, glomerulonephritis, glomerularsclerosis, nephrotic syndrome, psoriasis, obesity or dementia. Compounds disclosed herein also can inhibit aldose reductase. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and methods for treating diabetes mellitus and diseases and conditions mediated through insulin resistance are provided.
摘要翻译：本文提供具有PPAR激动剂活性的炔基衍生物，并且可用作抗糖尿病化合物。本文公开的化合物可用于治疗糖尿病和糖尿病相关并发症，其中胰岛素抵抗是病理生理学机制的疾病和病症，以及诸如II型糖尿病，血脂异常，高血压，冠心病，心血管疾病疾病，动脉粥样硬化，肾硬化，多囊卵巢综合症，进食障碍，糖尿病肾病，肾小球性肾炎，肾小球硬化症，肾病综合征，牛皮癣，肥胖或痴呆。本文公开的化合物还可以抑制醛糖还原酶。提供了制备所公开化合物的方法，含有所公开化合物的药物组合物，以及治疗糖尿病的方法以及通过胰岛素抵抗介导的疾病和病症。

7. 发明申请

WO2004106299A2 SUBSTITUTED PYRROLE DERIVATIVES 审中-公开
标题翻译：取代的吡咯衍生物
公开(公告)号：WO2004106299A2
公开(公告)日：2004-12-09
申请号：PCT/IB2004001761
申请日：2004-05-28
申请人： RANBAXY LAB LTD , SALMAN MOHAMMAD , SATTIGERI JITENDRA , KUMAR YATENDRA , ARYAN RAM CHANDER , RAMANATHAN VIKRAM KRISHNA , CHUGH ANITA
发明人： SALMAN MOHAMMAD , SATTIGERI JITENDRA , KUMAR YATENDRA , ARYAN RAM CHANDER , RAMANATHAN VIKRAM KRISHNA , CHUGH ANITA
IPC分类号： A61K31/366 , A61K31/40 , C07D207/00 , C07D207/34 , C07D401/12 , C07D405/06 , C07D405/14
CPC分类号： C07D207/34 , A61K31/40 , C07C69/716 , C07C69/738 , C07D401/12 , C07D403/04 , C07D405/06 , C07D405/14 , C07D413/04
摘要： The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.
摘要翻译：本发明涉及可用作3-羟基-3-甲基戊二酰辅酶A（HMG-CoA）还原酶抑制剂的取代吡咯衍生物。本文公开的化合物可用作胆固醇降低剂，并且可用于治疗胆固醇相关疾病和相关症状。提供了制备所公开化合物的方法，以及含有所公开化合物的药物组合物，以及治疗胆固醇相关疾病和相关症状的方法。

8. 发明申请

WO2004105752A1 SUBSTITUTED PYRROLE DERIVATIVES AS HMG-COA REDUCTASE INHIBITORS 审中-公开
标题翻译：作为HMG-COA还原酶抑制剂的取代的吡咯烷酮衍生物
公开(公告)号：WO2004105752A1
公开(公告)日：2004-12-09
申请号：PCT/IB2004/001754
申请日：2004-05-28
申请人： RANBAXY LABORATORIES LIMITED , SATTIGERI, Jitendra , SALMAN, Mohammad , KUMAR, Yatendra
发明人： SATTIGERI, Jitendra , SALMAN, Mohammad , KUMAR, Yatendra
IPC分类号： A61K31/4025
CPC分类号： C07D401/04 , C07D403/12 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/14 , C07D417/12 , C07D417/14
摘要： The present invention relates to substituted pyrrole derivatives of Formula (I), wherein (Y), with the proviso that one of R 2 , R 4 and R 5 is a heterocycle and with the further provision that if R 2 is not a heterocycle then either R 4 or R 5 alone is not unsubstituted pyridyl, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.
摘要翻译：本发明涉及式（I）的取代吡咯衍生物，其中（Y），条件是R 2，R 4和R 5中的一个是杂环，并且进一步规定如果R 2不是杂环，则R 4或R 5 单独不是未取代的吡啶基，其可以用作3-羟基-3-甲基戊二酰辅酶A（HMG-CoA）还原酶抑制剂。本文公开的化合物可用作胆固醇降低剂，并且可用于治疗胆固醇相关疾病和相关症状。提供了制备所公开化合物的方法，以及含有所公开化合物的药物组合物，以及治疗胆固醇相关疾病和相关症状的方法。

9. 发明申请

WO2003086271A2 AZOLE DERIVATIVES AS ANTIFUNGAL AGENTS 审中-公开
标题翻译：偶氮衍生物作为抗真菌剂
公开(公告)号：WO2003086271A2
公开(公告)日：2003-10-23
申请号：PCT/IB2002/001242
申请日：2002-04-17
申请人： RANBAXY LABORATORIES LIMITED , SALMAN, Mohammad , VERMA, Ashwani Kumar , RATTAN, Ashok
发明人： SALMAN, Mohammad , VERMA, Ashwani Kumar , RATTAN, Ashok
IPC分类号： A61K
CPC分类号： C07D249/08 , C07D231/12 , C07D233/56 , C07D401/14 , C07D403/06 , C07D403/12 , C07D403/14
摘要： The present invention relates to novel azole derivatives of Formula I, as potential antifungal agents.This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and / or preventing the fungal infections in mammals, preferably humans.
摘要翻译：本发明涉及式I的新型唑衍生物作为潜在的抗真菌剂。本发明还涉及含有本发明化合物的药物组合物及其在治疗和/或预防哺乳动物，优选人类中的真菌感染中的用途。

10. 发明申请

WO2003084541A1 CARBOXIMIDE DERIVATIVES AS USEFUL URO-SELECTIVE ALPHA-1A ADRENOCEPTOR BLOCKERS 审中-公开
标题翻译：碳酰亚胺衍生物作为有用的选择性ALPHA-1A ADRENOCEPTOR阻断剂
公开(公告)号：WO2003084541A1
公开(公告)日：2003-10-16
申请号：PCT/IB2002/001108
申请日：2002-04-08
申请人： RANBAXY LABORATORIES LIMITED , SALMAN, Mohammad , YADAV, Gyan Chand , SHARMA, Somesh , KAPKOTI, Gobind Singh , CHUGH, Anita , GUPTA, Jang Bahadur , ANAND, Nitya
发明人： SALMAN, Mohammad , YADAV, Gyan Chand , SHARMA, Somesh , KAPKOTI, Gobind Singh , CHUGH, Anita , GUPTA, Jang Bahadur , ANAND, Nitya
IPC分类号： A61K31/495
CPC分类号： C07D295/13
摘要： Novel carboximide derivatives, which selectively inhibit binding to the α -1A adrenergic receptor, a receptor which has been shown to be important in the treatment of benign prostatic hyperplasia. The compounds of the present invention are potentially useful in the treatment of benign prostatic hyperplasia.
摘要翻译：新型的甲酰亚胺衍生物，其选择性地抑制与α> -1A <肾上腺素能受体的结合，该受体已被证明在治疗良性前列腺增生中是重要的。本发明的化合物可用于治疗良性前列腺增生。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式